| HOME >> BIOLOGY >> TECHNOLOGY |
diverse set of monoclonal antibodies from patients infected with Lassa virus, which causes Lassa fever. These human antibodies will be evaluated for their ability to protect from the severe consequences of the disease, and could play a role in treatment or prevention of this illness in areas of West Africa where Lassa fever is common."
This is the third major award given to Tulane for Lassa virus research. Under the original two grants awarded in 2005 and 2009, the group developed and patented new recombinant proteins for Lassa virus and developed several viral detection products that have been deployed in Africa for clinical testing where most VHFs are endemic.
"We are extremely pleased to be part of this expanded collaboration and to have received the NIH contract," said Douglass Simpson, Corgenix President and CEO. "Building on the previous two grants for development of state-of-the-art diagnostic tests on multiple delivery platforms, this new contract will enable Tulane and the other collaborators to probe deeper into the mechanisms of the virus, which can ultimately lead to prevention of the disease."
"This important research will save lives and help prevent this deadly disease. Boston University School of Medicine is pleased to be collaborating with such an esteemed group of researchers," said Thomas Geisbert, Ph.D., Associate Director of the National Emerging Infectious Diseases Laboratories Institute at Boston University.
Lassa fever, a serious viral disease spread by contact with infected rodents, is estimated to infect hundreds of thousands of people per year across the countries of Sierra Leone, Guinea'/>"/>SOURCE Corgenix Medical Corporation
Copyright©2010 PR Newswire.
All rights reserved
Related biology technology :
1. Corgenix Secures $1,750,000 Asset Based Credit Facility Representing Initial Gross Proceeds of $1.109 Million
2. Corgenix Reports Third Quarter Fiscal 2009 Financial Results
3. Corgenix to Exhibit AspirinWorks(R) Test at ACC.09
4. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
5. Corgenix to Host Conference Call to Discuss Second Quarter Results
6. Corgenix Signs Collaboration With Battelle
7. Corgenix Receives Two Additional Patents on AtherOx(R) Technology
8. Corgenix to Host Conference Call to Discuss First Quarter Results
9. Corgenix to Exhibit AspirinWorks(R) Test, Discuss New CHARISMA Trial Results at AHA 2008 Meeting
10. Corgenix Receives Third U.S. Patent on AtherOx(R) Technology
11. Corgenix Reports Fiscal 2008 Financial Results
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |